Aptose Biosciences Presents Positive Phase 1/2 Clinical Trial Data for Tuspetinib Triplet Therapy in Newly Diagnosed AML at 2026 EHA Congress
Aptose Biosciences Inc. Files Form 8-K: Key Updates for Inve...
Sign in to continue:
Aptose Biosciences Inc. Files Form 8-K: Key Updates for Inve...
PDS Biotechnology Corporation Schedules 2026 Annual Meeting ...
Ramaco Resources Announces Details of Second Quarter Class B...
Rumble Inc. 2026 Annual Meeting Results: Key Points for Inve...
Functional Brands Inc. Receives Nasdaq Delisting Determinati...
Alpha Modus Holdings, Inc. Terminates At The Market Offering...
Telomir Pharmaceuticals Announces Peer-Reviewed Publication ...
Spyre Therapeutics Announces Promising Phase 2 Results for S...
Comtech Telecommunications Q3 Fiscal 2026 Financial Report: ...
Byrna Technologies Announces Major Sales and Marketing Reali...